Browse Drug Recalls
1,788 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 1,788 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 1,788 FDA drug recalls in 2019.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Nov 15, 2019 | Clobetasol Propionate Foam (Emulsion Formulation), 0.05% a) 50 g pack (NDC 68... | Defective delivery system; product is not foaming or is coming out as liquid. | Class III | Glenmark Pharmaceuticals Inc., USA |
| Nov 15, 2019 | Clobetasol Propionate Foam, 0.05%, a) 50 g pack (NDC 68462-608-27) and b) 100... | Defective delivery system; product is not foaming or is coming out as liquid. | Class III | Glenmark Pharmaceuticals Inc., USA |
| Nov 15, 2019 | Colostat, Homeopathic Remedy, 1 fl. oz. (30 mL) per bottle, 20% Ethanol, Dist... | Labeling mix-up - Indications on product label are incorrect. | Class III | Grato Holdings, Inc. |
| Nov 15, 2019 | Timolol Maleate Sterile Opthalmic Solution,USP 0.25%, 5 mL, Rx Only, For Topi... | Labeling: Label mix-up: A case of Timolol Maleate Sterile Ophthalmic solution USP 0.25%, 5ml, had... | Class III | Rising Pharmaceuticals, Inc. |
| Nov 15, 2019 | MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3... | Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP ... | Class II | Akorn, Inc. |
| Nov 15, 2019 | Timolol Maleate USP, 0.5%, 5 mL, Sterile Opthalmic Solution, Rx Only, For T... | Labeling: Label mix-up: A case of Timolol Maleate Sterile Ophthalmic solution USP 0.25%, 5ml, had... | Class III | Rising Pharmaceuticals, Inc. |
| Nov 14, 2019 | Yeast Arrest, Homeopathic Formula, Vaginal Support suppositories, packaged in... | cGMP violations | Class II | Wisconsin Pharmacal Company, LLC |
| Nov 14, 2019 | AVKARE Ranitidine Tablets, USP 300 mg Rx Only NDC Manufactured for: AvKARE, I... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | AVKARE Inc. |
| Nov 14, 2019 | AVKARE Ranitidine Tablets, USP 150 mg Rx Only Manufactured for: AvKARE, Inc. ... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | AVKARE Inc. |
| Nov 13, 2019 | Silver Bullet, Get Bigger and Harder, Works in Minutes, Lasts for Days, 10 ma... | Marketed Without an Approved NDA/ANDA; Product contains undeclared active ingredient - Sildenafil. | Class I | Natures Rx |
| Nov 13, 2019 | Ranitidine Oral Solution, USP, 150 mg/10 mL, [10 mL x 30 Unit Dose Cups per c... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API. | Class II | Precision Dose Inc. |
| Nov 12, 2019 | fentaNYL 500 mcg/250 mL (2 mcg/mL) BUPivacaine HCl 0.0625% 156.25 mg/250 mL (... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | Albuterol 1.25mg / Ipratropium 0.5mg/ Budesonide 0.25mg, 3ML Vial, For Inhala... | Lack of Processing Controls | Class II | Integrated Health Concepts Inc. dba Conversio H... |
| Nov 12, 2019 | fentaNYL 1500 mcg/30 mL (50 mcg/mL) 30 mL PCA Vial Preservative Free, Rx, QuV... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 500 mcg/250 mL (2 mcg/mL) Bupivacaine HCl 0.1% 250 mg/250 mL (1 mg/m... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | Albuterol 2.5mg / Budesonide 0.5mg, 3ML Vial, For Inhalation Only, Shake Well... | Lack of Processing Controls | Class II | Integrated Health Concepts Inc. dba Conversio H... |
| Nov 12, 2019 | fentaNYL 200 mcg/100 mL (2 mcg/mL) 0.125% Bupivacaine HCl 125 mg/100 mL (1.25... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 400 mcg/200 mL (2 mcg/mL) ROPivacaine HCl 0.2% 400 mg/200 mL (2 mg/m... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 500 mcg/250 mL (2 mcg/mL) ROPivacaine HCl 0.2% 500 mg/250 mL (2 mg/m... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | Albuterol 2.5mg / Ipratropium 0.75mg /Budesonide 0.25mg, 3ML Vial, For Inhala... | Lack of Processing Controls | Class II | Integrated Health Concepts Inc. dba Conversio H... |
| Nov 12, 2019 | fentaNYL 1500 mcg/30 mL (50 mcg/mL) 30 mL in 35 mL Syringe Preservative Free,... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 1000 mcg/100 mL (10 mcg/mL) in 0.9% Sodium Chloride 100 mL CADD Pres... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 100 mcg/2 mL (50 mcg/mL) Preservative Free, Rx, QuVA Pharma 1075 W... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | Albuterol 3.75mg / Ipratropium 0.75mg, 3ML Vial, For Inhalation Only, Convers... | Lack of Processing Controls | Class II | Integrated Health Concepts Inc. dba Conversio H... |
| Nov 12, 2019 | fentaNYL 200 mcg/100 mL (2 mcg/mL) BUPivacaine HCl 0.1% 100 mg/100 mL (1 mg/m... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | Formoterol 12mcg / Budesonide 0.5mg, 3.5ML Vial, For Inhalation Only, Shake W... | Lack of Processing Controls | Class II | Integrated Health Concepts Inc. dba Conversio H... |
| Nov 12, 2019 | Albuterol 1.25mg / Ipratropium 0.5mg, 2ML Vial, For Inhalation Only, Conversi... | Lack of Processing Controls | Class II | Integrated Health Concepts Inc. dba Conversio H... |
| Nov 12, 2019 | fentaNYL 2500 mcg/250 mL (10 mcg/mL) in 0.9% Sodium Chloride 250 mL Bag Prese... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 250 mcg/5 mL (50 mcg/mL), 5 mL Syringe, Preservative Free, Rx, QuVA... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 1000 mcg/20 mL (50 mcg/mL) 20 mL in 20 mL Syringe Preservative Free,... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 200 mcg/100 mL (2 mcg/mL) BUPivacaine HCl 0.125% 125 mg/100 mL (1.25... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 1000 mcg/100 mL (10 mcg/mL) in 0.9% Sodium Chloride Preservative Fre... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | Budesonide 0.4mg, 3ML Vial, For Inhalation Only, Conversio Health, San Luis O... | Lack of Processing Controls | Class II | Integrated Health Concepts Inc. dba Conversio H... |
| Nov 12, 2019 | Albuterol 2.5mg / Ipratropium 0.75mg /Budesonide 0.5mg, 3ML Vial, For Inhalat... | Lack of Processing Controls | Class II | Integrated Health Concepts Inc. dba Conversio H... |
| Nov 12, 2019 | fentaNYL 500 mcg/250 mL (2 mcg/mL) 0.125% BUPivacaine HCl 312.5 mg/250 mL (1.... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 400 mcg/200 mL (2 mcg/mL) 0.1% ROPivacaine HCl 200 mg/200 mL (1 mg/m... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | Albuterol 2.5mg / Ipratropium 0.75mg, 2ML Vial, For Inhalation Only, Conversi... | Lack of Processing Controls | Class II | Integrated Health Concepts Inc. dba Conversio H... |
| Nov 12, 2019 | fentaNYL 200 mcg/100 mL (2 mcg/mL) BUPivacaine HCl 0.1% 100 mg/100 mL (1 mg/m... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | Albuterol 2.5mg / Ipratropium 0.75mg/ Triamcinolone 0.5 mg 3ML Vial, For Inha... | Lack of Processing Controls | Class II | Integrated Health Concepts Inc. dba Conversio H... |
| Nov 12, 2019 | fentaNYL 400 mcg/200 mL (2 mcg/mL) ROPivacaine HCl 0.1% 200 mg/200 mL (1 mg/m... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 550 mcg/55 mL (10 mcg/mL) in 0.9% Sodium Chloride 55 mL Syringe Pres... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | Fluphenazine Decanoate Injection USP 125mg/5mL, (5 mL Multiple Dose Vial), Rx... | Discoloration; Hazy solution found in one vial instead of a clear solution. | Class II | AuroMedics Pharma LLC |
| Nov 12, 2019 | fentaNYL 800 mcg/200 mL (4 mcg/mL) BUPivacaine HCl 0.1667% 333.4 mg/200 mL (1... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 200 mcg/100 mL (2 mcg/mL) ROPivacaine HCl 0.2% 200 mg/100 mL (2 mg/m... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 1250 mcg/250 mL (5 mcg/mL) in 0.9% Sodium Chloride 250 mL Bag Preser... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 200 mcg/100 mL (2 mcg/mL) ROPivacaine HCl 0.2% 200 mg/100 mL (2 mg/m... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 2500 mcg/50 mL (50 mcg/mL) 50 mL bag, Preservative Free, Rx, QuVA Ph... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 2750 mcg/55 mL (50 mcg/mL) 55 mL Syringe, Preservative Free, Rx, QuV... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 12, 2019 | fentaNYL 2000 mcg/100 mL (20 mcg/mL) in 0.9% Sodium Chloride, 100 mL Bag, Pre... | Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass par... | Class II | QuVa Pharma, Inc. |
| Nov 11, 2019 | Amiodarone Hydrochloride Injection, USP, 900 mg per 18 mL (50 mg / mL), 18 mL... | Crystallization: Presence of visible particulate matter. | Class III | AuroMedics Pharma LLC |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.